<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36004011</PMID><DateRevised><Year>2022</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Persistent Relapsing Immune Thrombocytopenia Following COVID-19 Infection.</ArticleTitle><Pagination><StartPage>e27133</StartPage><MedlinePgn>e27133</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e27133</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.27133</ELocationID><Abstract><AbstractText>Immune thrombocytopenia (ITP) is a rare autoimmune disease that presents along a spectrum of disease severity, ranging from asymptomatic thrombocytopenia to potentially life-threatening bleeding complications. Recent case reports and case series suggest that a COVID-19 infection can trigger secondary ITP&#xa0;and may be associated with higher rates of bleeding and lower nadir platelet counts compared to patients with ITP of other etiologies. Multiple ITP relapses have also been described in some COVID-19 patients. We report the case of a 30-year-old otherwise healthy woman who presented to the hospital with fatigue, easy bruising, and a platelet count of 11 x 10<sup>3</sup>/&#xb5;L. She responded well to our initial treatment with prednisone and intravenous immunoglobulin (IVIG) but experienced a persistent disease course with nine ITP relapses (defined as platelet count &lt;30 x 10<sup>3</sup>/&#xb5;L) over the next 10.5 months, requiring six additional hospital admissions for acute management as well as long-term maintenance medication adjustments. It is important for clinicians to recognize ITP as a potential complication of a COVID-19 infection and to initiate early therapy to prevent serious bleeding in these patients. Further studies will be needed to understand the natural history, optimal treatment, and prognosis for patients with relapsing COVID-19-associated ITP.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Boehm et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boehm</LastName><ForeName>Blake A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Medicine, Case Western Reserve University School of Medicine, Cleveland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Packer</LastName><ForeName>Clifford D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Internal Medicine, Case Western Reserve University School of Medicine, Cleveland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic itp</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019 (covid-19)</Keyword><Keyword MajorTopicYN="N">covid</Keyword><Keyword MajorTopicYN="N">covid 19</Keyword><Keyword MajorTopicYN="N">covid associated thrombocytopenia</Keyword><Keyword MajorTopicYN="N">immune thrombocytopenia (itp)</Keyword><Keyword MajorTopicYN="N">immune thrombocytopenia purpura</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">persistent itp</Keyword><Keyword MajorTopicYN="N">refractory itp</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>2</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36004011</ArticleId><ArticleId IdType="pmc">PMC9392851</ArticleId><ArticleId IdType="doi">10.7759/cureus.27133</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Immune thrombocytopenic purpura. Cines DB, Blanchette VS. N Engl J Med. 2002;346:995&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">11919310</ArticleId></ArticleIdList></Reference><Reference><Citation>Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. K&#xfc;hne T, Berchtold W, Michaels LA, et al. Haematologica. 2011;96:1831&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232266</ArticleId><ArticleId IdType="pubmed">21880634</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune thrombocytopenia. Cooper N, Ghanima W. N Engl J Med. 2019;381:945&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">31483965</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Schoonen WM, Kucera G, Coalson J, et al. Br J Haematol. 2009;145:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">19245432</ArticleId></ArticleIdList></Reference><Reference><Citation>The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Frederiksen H, Schmidt K. Blood. 1999;94:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">10419881</ArticleId></ArticleIdList></Reference><Reference><Citation>American Society of Hematology 2019 guidelines for immune thrombocytopenia. Neunert C, Terrell DR, Arnold DM, et al. Blood Adv. 2019;3:3829&#x2013;3866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6963252</ArticleId><ArticleId IdType="pubmed">31794604</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D, Cuker A, Crowther M, Tirnauer J. UpToDate. Waltham, MA: UpToDate; 2022. Second-line and subsequent therapies for immune thrombocytopenia (ITP) in adults.</Citation></Reference><Reference><Citation>A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Rodeghiero F. Br J Haematol. 2018;181:183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">29479668</ArticleId></ArticleIdList></Reference><Reference><Citation>Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Sun L, Mack J, Li A, et al. Blood Adv. 2019;3:1512&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517661</ArticleId><ArticleId IdType="pubmed">31076407</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanism of thrombocytopenia in COVID-19 patients. Xu P, Zhou Q, Xu J. Ann Hematol. 2020;99:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156897</ArticleId><ArticleId IdType="pubmed">32296910</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19: from an acute to chronic disease? Potential long-term health consequences. Higgins V, Sohaei D, Diamandis EP, Prassas I. Crit Rev Clin Lab Sci. 2021;58:297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">33347790</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. Baig AM. ACS Chem Neurosci. 2020;11:4017&#x2013;4020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID, a comprehensive systematic scoping review. Akbarialiabad H, Taghrir MH, Abdollahi A, et al. Infection. 2021;49:1163&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317481</ArticleId><ArticleId IdType="pubmed">34319569</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune thrombocytopenia and COVID-19: case report and review of literature. Alonso-Beato R, Morales-Ortega A, Fern&#xe1;ndez FJ, Mor&#xf3;n AI, R&#xed;os-Fern&#xe1;ndez R, Rubio JL, Centeno NO. Lupus. 2021;30:1515&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">34053365</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience. Kewan T, Gunaratne TN, Mushtaq K, Alayan D, Daw H, Haddad A. Transfusion. 2021;61:2014&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250532</ArticleId><ArticleId IdType="pubmed">33724474</ArticleId></ArticleIdList></Reference><Reference><Citation>Frequently relapsing post-COVID-19 immune thrombocytopenia. Serrano C, Espa&#xf1;ol I, Cascales A, Moraleda JM. SN Compr Clin Med. 2021;3:2389&#x2013;2392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294309</ArticleId><ArticleId IdType="pubmed">34308259</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Mah&#xe9;vas M, Moulis G, Andres E, et al. Br J Haematol. 2020;190:0&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404899</ArticleId><ArticleId IdType="pubmed">32678953</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune thrombocytopenia purpura secondary to COVID-19. Bennett J, Brown C, Rouse M, Hoffmann M, Ye Z. Cureus. 2020;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362597</ArticleId><ArticleId IdType="pubmed">32676257</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>